FDA's 503B Bulks List Exclusion for GLP-1s Nears Decision as Compounding Window Stays Shut

What Happened

The US Food and Drug Administration has proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the register of active ingredients that large-scale outsourcing facilities may use to compound medicines in bulk. The agency's stated reason is direct: after reviewing the nominations it received, it did not identify a clinical need for factory-scale compounding of the three GLP-1 molecules when FDA-approved products are commercially available.

The proposal, announced April 30 and published in the Federal Register May 1, would close the last regulatory door that could reopen mass compounding of these drugs after a future market disruption. It does not touch patient-specific 503A pharmacy prescriptions, which remain governed by state boards under the "essentially a copy" restrictions that already bar routine copying of approved drugs.

Regulatory filings show the comment period was extended to July 30, 2026. No final determination has been published — the rule remains a proposal, and the agency has said it will weigh submitted comments before deciding. The pending decision is drawing renewed international attention as telehealth sellers continue advertising compounded injectables.

Who Is Affected

• 503B outsourcing facilities — the proposal removes the bulk-substance pathway for all three molecules regardless of future shortage status, once finalized.
• Telehealth platforms built on compounded GLP-1 supply — the mass-market pipeline scaled during the 2022-2024 shortages now faces permanent closure.
• Patients using compounded GLP-1s — unapproved copies carry no FDA-verified identity, purity, or potency, and agency data have linked multi-dose vials to dosing errors.
• Novo Nordisk and Eli Lilly — the makers of the approved products have publicly backed the exclusion.
• 503A compounding pharmacies — largely unaffected by this specific rule, but already constrained by the copy restrictions that ended shortage-era mass production.

Timeline

• 2022-2024 — GLP-1 shortages place semaglutide and tirzepatide on the FDA shortage list, opening temporary compounding flexibility.
• October 2024 - February 2025 — FDA declares the shortages resolved; enforcement discretion windows close by May 22, 2025.
• April 30, 2026 — FDA announces the proposed bulks-list exclusion for all three molecules.
• July 30, 2026 — Extended comment window closes; the docket moves to agency review.
• October 2026 — No final determination published; enforcement letters continue against individual compounders.

What This Means for Researchers

If finalized, the exclusion would be permanent rather than shortage-dependent — a future supply hiccup would not automatically reauthorize bulk compounding of these molecules. That is the structural change: the pathway that created the gray GLP-1 market would not simply reopen when conditions change.

For research sourcing, the signal is consistency. Bulk-compounded GLP-1 copies are on a path to permanent regulatory exclusion, and materials sold as "research-grade" semaglutide or tirzepatide sit in a supply chain without batch-level sterility and identity verification. Labs evaluating peptide suppliers should treat 503B compounding claims for these molecules as increasingly tenuous and verify any certificate of analysis independently.

How to Verify Your Peptides

Independent testing remains the only real check on what is in a vial:

• Understand how peptide testing works and what a certificate of analysis actually demonstrates.
• Compare methods before trusting results — see HPLC vs LC-MS testing.
• Check our semaglutide purity testing guide for molecule-specific verification points.
• Review identity, purity, and fill-weight testing before any acquisition.

Safe Alternatives

• Approved, registered pharmaceutical products remain the reference standard — our semaglutide overview covers the approved landscape.
• For research compounds outside the approved-drug framework, see the peptide research library.
• When sourcing through third parties, consult the vendor directory.

Sources

Regulatory announcements from the US Food and Drug Administration (Federal Register notice 2026-08552). Industry reports on the 503B bulks-list docket.